Transgene SA (EPA:TNG)
France · Delayed Price · Currency is EUR | Market Cap | 207.33M +144.8% |
| Revenue (ttm) | 7.21M +13.5% |
| Net Income | -37.52M |
| EPS | -0.26 |
| Shares Out | 273.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,365 |
| Average Volume | 51,045 |
| Open | 0.7600 |
| Previous Close | 0.7570 |
| Day's Range | 0.7550 - 0.7600 |
| 52-Week Range | 0.5300 - 1.5000 |
| Beta | 0.73 |
| RSI | 44.91 |
| Earnings Date | Apr 29, 2026 |
About Transgene
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastroi... [Read more]
Financial Performance
In 2025, Transgene's revenue was 7.21 million, an increase of 13.49% compared to the previous year's 6.35 million. Losses were -37.52 million, 10.5% more than in 2024.
Financial StatementsNews
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
STRASBOURG, France--(BUSINESS WIRE)---- $TNG--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced tha...
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
BioInvent and Transgene Joint Paper on BT-001 Wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022
Winning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022 Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and Bi...
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
STRASBOURG, France--(BUSINESS WIRE)-- #HBV--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces...
R&D Day: Presentations to Highlight Transgene's Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
STRASBOURG, France--(BUSINESS WIRE)-- #HBV--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, wil...
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
STRASBOURG, France--(BUSINESS WIRE)---- $TNG--New positive TG6002 Phase I data confirm the mechanism of action of this oncolytic virus when administered intravenously.